GuidelineHaematologica2013
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).
Guideline in Haematologica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed, 5 syntheses or guidelines pooled it, 358 citations in OpenAlex.
- Temporal trends and prognostic factors in critically ill adult patients with acute leukemia: an individual participant data meta-analysis.Intensive care medicine · 2026Pooled it
- Mucormycosis in Paediatric Patients After Haematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.Mycoses · 2025Pooled it
- Pooled it
- Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.The Lancet. Infectious diseases · 2019Guideline
- ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.Haematologica · 2017Guideline
- Dual Invasive Fungal Infections After Kidney Transplantation: A Case Report.Journal of fungi (Basel, Switzerland) · 2026Article
- Article
- Invasive transmural fungal infection as a rare cause of thoracic aortic occlusion.Journal of vascular surgery cases and innovative techniques · 2026Article
- Mannan immunoassay for diagnosis of invasive mucormycosis: assay development, preclinical testing and evaluation in an animal model.Frontiers in cellular and infection microbiology · 2026Article
- Pathogenic mucorales: Deciphering their cell wall polysaccharidome and immunostimulatory potential.Virulence · 2025Article
- A clinical presentation of rhino-orbito-cerebral mucormycosis in a patient with aplastic anemia: a case report.Journal of medical case reports · 2025Article
- Monoclonal Antibodies Can Aid in the Culture-Based Detection and Differentiation ofAntibodies (Basel, Switzerland) · 2025Article
- Can We Have Guidelines or Just Guidance for Rare Fungal Infections?Journal of fungi (Basel, Switzerland) · 2025Article
- Invasive Sphenoid Sinus Aspergillosis in a Patient With Chronic Neutropenia: A Case Report.Cureus · 2025Article
- Rare case of hard palate mucomycosis complicated by peri-orbital swelling: A diagnostic challenge.Radiology case reports · 2025Article
- Outcomes of COVID-19-associated mucormycosis epidemic in India: A prospective 2-year follow-up study.World journal of otorhinolaryngology - head and neck surgery · 2025Article
- Role of the putativeMicrobial cell (Graz, Austria) · 2025Article
- Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.Annals of medicine · 2024Review
- Functional characterization of two survival factor 1 genes inMicrobiology spectrum · 2024Article
- Cerebritis, optic ischemia, and cavernous sinus thrombosis arising from sinonasal mucormycosis.Radiology case reports · 2024Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis is an emerging cause of infectious morbidity and mortality in patients with hematologic malignancies. However, there are no recommendations to guide diagnosis and management. The European Conference on Infections in Leukemia assigned experts in hematology and infectious diseases to develop evidence-based recommendations for the diagnosis and treatment of mucormycosis. The guidelines were developed using the evidence criteria set forth by the American Infectious Diseases Society and the key recommendations are summarized here. In the absence of validated biomarkers, the diagnosis of mucormycosis relies on histology and/or detection of the organism by culture from involved sites with identification of the isolate at the species level (no grading). Antifungal chemotherapy, control of the underlying predisposing condition, and surgery are the cornerstones of management (level A II). Options for first-line chemotherapy of mucormycosis include liposomal amphotericin B and amphotericin B lipid complex (level B II). Posaconazole and combination therapy of liposomal amphotericin B or amphotericin B lipid complex with caspofungin are the options for second line-treatment (level B II). Surgery is recommended for rhinocerebral and skin and soft tissue disease (level A II). Reversal of underlying risk factors (diabetes control, reversal of neutropenia, discontinuation/taper of glucocorticosteroids, reduction of immunosuppressants, discontinuation of deferroxamine) is important in the treatment of mucormycosis (level A II). The duration of antifungal chemotherapy is not defined but guided by the resolution of all associated symptoms and findings (no grading). Maintenance therapy/secondary prophylaxis must be considered in persistently immunocompromised patients (no grading).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.